---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-077200"
form_type: "8-K"
ticker: "SGMT"
cik: "0001400118"
company_name: "Sagimet Biosciences Inc."
filed_at: "2025-08-13T23:59:59+00:00"
generated_at: "2026-05-17T13:53:40.145310+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Sagimet Q2 net loss $10.4M, cash $135.5M; denifanstat meets all acne Phase 3 endpoints

## Summary
- Net loss Q2 2025 $10.4M vs $8.1M; H1 loss $28.6M vs $14.7M; R&D and G&A both increased.
- Cash position $135.5M at June 30, 2025; no revenue reported (pre-revenue biotech).
- Denifanstat Phase 3 acne trial (Ascletis) met all endpoints: treatment success 33.2% vs 14.6% (p<0.0001).
- Initiated Phase 1 for TVB-3567 (acne) in U.S.; combo trial denifanstat+resmetirom PK study planned 2H 2025 with readout 1H 2026.

## SEC filing metadata
- accession: 0001104659-25-077200
- form_type: 8-K
- ticker: SGMT
- cik: 0001400118
- company_name: Sagimet Biosciences Inc.
- filed_at: 2025-08-13T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1400118/000110465925077200/0001104659-25-077200-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1400118/000110465925077200/tm2523275d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-077200
- JSON: https://secwatch.observer/filing/0001104659-25-077200.json
- Plain text: https://secwatch.observer/filing/0001104659-25-077200.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.